Reported by Jules Levin 13th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV 14-16 July 2011-Rome, Italy

Conference Reports for NATAP


13th Intl Workshop on Adverse Reactions & Comorbidities in HIV July 2011-Rome, Italy

	Metabolic Risk Factors in Responders to Tesamorelin, a Growth Hormone-Releasing Factor (GRF) Analogue, in HIV-Infected Patients with Excess Abdominal Fat - (07/17/11) Bone Mineral Density (BMD) Analysis in Antiretroviral (ART)-Naïve Subjects Taking Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS Study - (07/17/11)